310 related articles for article (PubMed ID: 12083745)
1. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor.
Sugimoto H; Ogura H; Arai Y; Limura Y; Yamanishi Y
Jpn J Pharmacol; 2002 May; 89(1):7-20. PubMed ID: 12083745
[TBL] [Abstract][Full Text] [Related]
2. Donepezil hydrochloride: a treatment drug for Alzheimer's disease.
Sugimoto H
Chem Rec; 2001; 1(1):63-73. PubMed ID: 11893059
[TBL] [Abstract][Full Text] [Related]
3. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors.
Sugimoto H; Yamanishi Y; Iimura Y; Kawakami Y
Curr Med Chem; 2000 Mar; 7(3):303-39. PubMed ID: 10637367
[TBL] [Abstract][Full Text] [Related]
4. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.
Sugimoto H
Chem Biol Interact; 2008 Sep; 175(1-3):204-8. PubMed ID: 18577377
[TBL] [Abstract][Full Text] [Related]
5. [Discovery and development of donepezil hydrochloride for the treatment of Alzheimer's disease].
Sugimoto H; Yamanishi Y; Ogura H; Iimura Y; Yamatsu K
Yakugaku Zasshi; 1999 Feb; 119(2):101-13. PubMed ID: 10067428
[TBL] [Abstract][Full Text] [Related]
6. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.
Bautista-Aguilera OM; Esteban G; Chioua M; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Soriano E; Samadi A; Unzeta M; Marco-Contelles J
Drug Des Devel Ther; 2014; 8():1893-910. PubMed ID: 25378907
[TBL] [Abstract][Full Text] [Related]
7. The pharmacology of donepezil: a new treatment of Alzheimer's disease.
Wilkinson DG
Expert Opin Pharmacother; 1999 Nov; 1(1):121-35. PubMed ID: 11249555
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Darreh-Shori T; Hosseini SM; Nordberg A
J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
[TBL] [Abstract][Full Text] [Related]
9. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
Rogers SL
Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
[TBL] [Abstract][Full Text] [Related]
10. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Ogura H; Kosasa T; Kuriya Y; Yamanishi Y
Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):609-13. PubMed ID: 11256231
[TBL] [Abstract][Full Text] [Related]
11. Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles.
Shigeta M; Homma A
CNS Drug Rev; 2001; 7(4):353-68. PubMed ID: 11830754
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological properties of donepezil hydrochloride (Aricept), a drug for Alzheimer's disease].
Ogura H; Kosasa T; Araki S; Yamanishi Y
Nihon Yakurigaku Zasshi; 2000 Jan; 115(1):45-51. PubMed ID: 10876815
[TBL] [Abstract][Full Text] [Related]
13. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.
Kryger G; Silman I; Sussman JL
Structure; 1999 Mar; 7(3):297-307. PubMed ID: 10368299
[TBL] [Abstract][Full Text] [Related]
14. Donepezil: an update.
Seltzer B
Expert Opin Pharmacother; 2007 May; 8(7):1011-23. PubMed ID: 17472546
[TBL] [Abstract][Full Text] [Related]
15. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activity of new donepezil-hydrazinonicotinamide hybrids.
Zurek E; Szymański P; Mikiciuk-Olasik E
Drug Res (Stuttg); 2013 Mar; 63(3):137-44. PubMed ID: 23447117
[TBL] [Abstract][Full Text] [Related]
17. Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors.
Kaur J; Zhang MQ
Curr Med Chem; 2000 Mar; 7(3):273-94. PubMed ID: 10637365
[TBL] [Abstract][Full Text] [Related]
18. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Nordberg A; Darreh-Shori T; Peskind E; Soininen H; Mousavi M; Eagle G; Lane R
Curr Alzheimer Res; 2009 Feb; 6(1):4-14. PubMed ID: 19199870
[TBL] [Abstract][Full Text] [Related]
19. Targeting Alzheimer's disease by investigating previously unexplored chemical space surrounding the cholinesterase inhibitor donepezil.
van Greunen DG; Cordier W; Nell M; van der Westhuyzen C; Steenkamp V; Panayides JL; Riley DL
Eur J Med Chem; 2017 Feb; 127():671-690. PubMed ID: 27823887
[TBL] [Abstract][Full Text] [Related]
20. Metformin and its sulphonamide derivative simultaneously potentiateanti-cholinesterase activity of donepezil and inhibit beta-amyloid aggregation.
Markowicz-Piasecka M; Huttunen KM; Sikora J
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1309-1322. PubMed ID: 30251898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
